Equity capital markets

Helius Medical Technologies, Inc. Announces Pricing of $6.4 Million Public Offering

Retrieved on: 
星期二, 五月 7, 2024
HSDT, Sale, Prospectus, Suite, Form, Common stock, Venture round, Equity capital markets, Capital Group Companies, Telephone, Security (finance)

The public offering price per share of Common Stock and accompanying Series A and Series B warrants is $2.25 and the public offering price per Pre-Funded Warrant and accompanying Series A and Series B warrant is $2.249, resulting in gross proceeds of approximately $6.4 million before deducting the placement agent's fees and other estimated offering expenses.

Key Points: 
  • The public offering price per share of Common Stock and accompanying Series A and Series B warrants is $2.25 and the public offering price per Pre-Funded Warrant and accompanying Series A and Series B warrant is $2.249, resulting in gross proceeds of approximately $6.4 million before deducting the placement agent's fees and other estimated offering expenses.
  • The offering is expected to close on or about May 9, 2024, subject to customary closing conditions.
  • The Company intends to use the net proceeds from this offering for funding operations, working capital and other general corporate purposes.
  • Craig-Hallum Capital Group LLC is acting as the sole placement agent for the offering.

Skyward Specialty Announces Pricing of Its Secondary Offering of Its Common Stock

Retrieved on: 
星期二, 五月 7, 2024
4th floor, Sale, Prospectus, Keefe, Bruyette & Woods, Broadridge Financial Solutions, Security (finance), Jefferies, Barclays, Form S-3, Madison Avenue, TD Securities, Form, Exercise, JMP, Jefferies Group, Equity capital markets, Attention, Telephone

HOUSTON, May 06, 2024 (GLOBE NEWSWIRE) -- Skyward Specialty Insurance Group, Inc. (NASDAQ: SKWD) (“Skyward Specialty” or the “Company”) a leader in the specialty property and casualty (“P&C”) market, announced the pricing of its secondary offering of 4,400,000 shares being offered by The Westaim Corporation, through its wholly-owned subsidiary, Westaim HIIG GP Inc. (the “Selling Stockholder”) at $36.50.

Key Points: 
  • HOUSTON, May 06, 2024 (GLOBE NEWSWIRE) -- Skyward Specialty Insurance Group, Inc. (NASDAQ: SKWD) (“Skyward Specialty” or the “Company”) a leader in the specialty property and casualty (“P&C”) market, announced the pricing of its secondary offering of 4,400,000 shares being offered by The Westaim Corporation, through its wholly-owned subsidiary, Westaim HIIG GP Inc. (the “Selling Stockholder”) at $36.50.
  • In connection with the offering, the Selling Stockholder has also granted the underwriters a 30-day option to purchase up to an additional 660,000 shares of Skyward Specialty's common stock.
  • The Selling Stockholder will hold 4.80% and 6.45% in Skyward Specialty, assuming full and no exercise of the underwriters’ option to purchase the additional shares, respectively.
  • Barclays, Keefe, Bruyette & Woods, Inc., A Stifel Company, and Jefferies are acting as joint lead book-running managers for the proposed offering.

Skyward Specialty Announces Secondary Offering of Its Common Stock

Retrieved on: 
星期一, 五月 6, 2024
4th floor, Sale, Prospectus, Keefe, Bruyette & Woods, Broadridge Financial Solutions, Security (finance), Jefferies, Barclays, Form S-3, Madison Avenue, Form, Exercise, Jefferies Group, Equity capital markets, Attention, Telephone

HOUSTON, May 06, 2024 (GLOBE NEWSWIRE) -- Skyward Specialty Insurance Group, Inc. (NASDAQ: SKWD) (“Skyward Specialty” or the “Company”) a leader in the specialty property and casualty (“P&C”) market, announced that The Westaim Corporation (“Westaim”), through its wholly-owned subsidiary, Westaim HIIG GP Inc. (the “Selling Stockholder”) is offering 4,400,000 shares of the Company’s common stock in an underwritten secondary public offering.

Key Points: 
  • HOUSTON, May 06, 2024 (GLOBE NEWSWIRE) -- Skyward Specialty Insurance Group, Inc. (NASDAQ: SKWD) (“Skyward Specialty” or the “Company”) a leader in the specialty property and casualty (“P&C”) market, announced that The Westaim Corporation (“Westaim”), through its wholly-owned subsidiary, Westaim HIIG GP Inc. (the “Selling Stockholder”) is offering 4,400,000 shares of the Company’s common stock in an underwritten secondary public offering.
  • In connection with the offering, the Selling Stockholder has also granted the underwriters a 30-day option to purchase up to an additional 660,000 shares of Skyward Specialty's common stock.
  • The Selling Stockholder will be a 4.80% and 6.45% shareholder in Skyward Specialty, assuming full and no exercise of the underwriters’ option to purchase the additional shares, respectively.
  • Skyward Specialty will not receive any of the proceeds from the sale of the shares of its common stock offered by the Selling Stockholder, and the Selling Stockholder will bear the underwriting discounts and commissions associated with the sale of such shares.

D.A. Davidson Hires Gary Morabito to Lead Technology Equity Capital Markets

Retrieved on: 
星期一, 五月 6, 2024
Technology, Mobile, Wireless, Finance, Consulting, Banking, Other Consumer, Professional Services, Semiconductor, Security, Satellite, Photography, Nanotechnology, Audio, Video, Other Technology, Telecommunications, Consumer, Software, Networks, Internet, Hardware, Electronic Design Automation, Data Management, VoIP, The Herd, Denison University, Investment banking, Institutional research, Capital market, Economics, DEN, Research, ECM, Equity capital markets, Multimedia, Dislocation, Research fellow, Herd, Financial services

Davidson & Co. announced that Gary Morabito has joined the Equity Capital Markets Group as Managing Director.

Key Points: 
  • Davidson & Co. announced that Gary Morabito has joined the Equity Capital Markets Group as Managing Director.
  • Davidson as Managing Director to lead Equity Capital Markets for emerging private and public technology companies.
  • “Gary has demonstrated experience and leadership in equity capital markets,” commented Tim Monfort, Managing Director at D.A.
  • Davidson & Co.’s Equity Capital Markets group provides a full-service platform offering expertise to middle-market companies across four industries of focus: consumer, diversified industrials, financial institutions, and technology.

Intra-Cellular Therapies Announces Closing of $575 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

Retrieved on: 
星期三, 四月 24, 2024
Sale, Prospectus, J.P. Morgan & Co., RBC Capital Markets, Broadridge Financial Solutions, Morgan Stanley, Vesey Street, Canaccord Genuity, Security (finance), SVB Securities, Form S-3, CNS, Form, Exercise, Therapy, Varick Street, Equity capital markets, Cantor, 2nd Floor, State Street, Central nervous system, BofA Securities, Attention, Telephone, File, Needham & Company

All of the shares in the public offering, including the full exercise of the underwriters’ option, were sold by Intra-Cellular Therapies, with gross proceeds to Intra-Cellular Therapies of approximately $575 million, before deducting underwriting discounts and commissions and offering expenses.

Key Points: 
  • All of the shares in the public offering, including the full exercise of the underwriters’ option, were sold by Intra-Cellular Therapies, with gross proceeds to Intra-Cellular Therapies of approximately $575 million, before deducting underwriting discounts and commissions and offering expenses.
  • J.P. Morgan, Leerink Partners, BofA Securities, Morgan Stanley and RBC Capital Markets acted as joint book-running managers for the offering.
  • Cantor, Mizuho, Canaccord Genuity and Needham & Company acted as co-managers for the offering.
  • The public offering was made pursuant to a shelf registration statement on Form S-3 (including a base prospectus) that was previously filed with the Securities and Exchange Commission (the “SEC”) and became effective upon filing.

Centessa Pharmaceuticals Announces Pricing of $100 Million Public Offering of American Depositary Shares

Retrieved on: 
星期三, 四月 24, 2024
Goldman Sachs, Sale, Prospectus, Equity, BMO Capital Markets, CNTA, Security (finance), Guggenheim Partners, SVB Securities, Madison Avenue, Floor, Form, ADS, American depositary receipt, Patient, Equity capital markets, Evercore, State Street, Attention, Telephone

The aggregate gross proceeds to Centessa from this offering are expected to be approximately $100 million, before deducting underwriting discounts and commissions and offering expenses payable by Centessa.

Key Points: 
  • The aggregate gross proceeds to Centessa from this offering are expected to be approximately $100 million, before deducting underwriting discounts and commissions and offering expenses payable by Centessa.
  • All ADSs sold in the offering were offered by Centessa.
  • Centessa has also granted the underwriters a 30-day option to purchase up to an additional 1,621,621 ADSs at the public offering price, less underwriting discounts and commissions.
  • Goldman Sachs, Leerink Partners, Evercore ISI, Guggenheim Securities and BMO Capital Markets are acting as joint book-running managers for the offering.

Lithium Americas Prices US$275 Million Underwritten Public Offering

Retrieved on: 
星期四, 四月 18, 2024
Lithium, Form, Thacker Pass Lithium Mine, Indian stock exchange, News, TSX, J. P. Morgan, GM, Equity capital markets, Telephone, Goldman Sachs, Increment, Offering, Canaccord Genuity, Public expenditure, Exercise, Evercore, Attention, Sale, Loan, BMO Capital Markets, Toronto Stock Exchange, Register, Scotiabank, Security (finance)

VANCOUVER, British Columbia, April 18, 2024 (GLOBE NEWSWIRE) -- Lithium Americas Corp. (TSX: LAC) (NYSE: LAC) (“Lithium Americas” or the “Company”) announced the pricing of its previously announced underwritten public offering (the “Offering”) of 55,000,000 of its common shares (the “Common Shares”) at a price to the public of $5.00 per Common Share (the “Issue Price”) for aggregate gross proceeds to the Company of $275,000,000.

Key Points: 
  • VANCOUVER, British Columbia, April 18, 2024 (GLOBE NEWSWIRE) -- Lithium Americas Corp. (TSX: LAC) (NYSE: LAC) (“Lithium Americas” or the “Company”) announced the pricing of its previously announced underwritten public offering (the “Offering”) of 55,000,000 of its common shares (the “Common Shares”) at a price to the public of $5.00 per Common Share (the “Issue Price”) for aggregate gross proceeds to the Company of $275,000,000.
  • The Company intends to use the net proceeds of the Offering for advancing the construction and development of its Thacker Pass lithium project in Humboldt County, Nevada (“Thacker Pass”), as further described in the Prospectus Supplements.
  • The Offering will be made in the United States by way of a prospectus supplement (the “U.S.
  • The Prospectus Supplements, the Base Shelf Prospectuses and the Registration Statement contain important information about the Company and the proposed Offering.

Intra-Cellular Therapies Prices Public Offering of Common Stock

Retrieved on: 
星期四, 四月 18, 2024
Sale, Prospectus, J.P. Morgan & Co., RBC Capital Markets, Broadridge Financial Solutions, Morgan Stanley, Vesey Street, Canaccord Genuity, Security (finance), SVB Securities, Form S-3, CNS, Form, Therapy, Varick Street, Equity capital markets, Cantor, 2nd Floor, State Street, Central nervous system, BofA Securities, Attention, Telephone, File, Needham & Company

NEW YORK, April 17, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI) (“Intra-Cellular Therapies”), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced the pricing of its previously announced underwritten public offering of 6,849,316 shares of its common stock at a public offering price of $73.00 per share.

Key Points: 
  • NEW YORK, April 17, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI) (“Intra-Cellular Therapies”), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced the pricing of its previously announced underwritten public offering of 6,849,316 shares of its common stock at a public offering price of $73.00 per share.
  • All of the shares in the offering will be sold by Intra-Cellular Therapies, with gross proceeds to Intra-Cellular Therapies expected to be $500.0 million before deducting underwriting discounts and commissions and offering expenses.
  • Intra-Cellular Therapies has granted the underwriters a 30-day option to purchase up to an additional 1,027,397 shares on the same terms and conditions.
  • J.P. Morgan, Leerink Partners, BofA Securities, Morgan Stanley and RBC Capital Markets are acting as joint book-running managers for the offering.

Lithium Americas Announces Proposed Public Offering of Common Shares

Retrieved on: 
星期三, 四月 17, 2024
Lithium, Goldman Sachs, Sale, Offering, Lithium Corporation of America, News, BMO Capital Markets, TSX, Indian stock exchange, Form, Equity capital markets, Evercore, Register, Attention, Telephone, Security (finance)

VANCOUVER, British Columbia, April 17, 2024 (GLOBE NEWSWIRE) -- Lithium Americas Corp. (TSX: LAC) (NYSE: LAC) (“Lithium Americas” or the “Company”) announced that it intends to offer and sell, subject to market conditions, 55,000,000 of its common shares (the “Common Shares”) in an underwritten public offering (the “Offering”). All of the Common Shares to be sold in the Offering will be offered by Lithium Americas. The Offering is subject to market and other conditions, and there can be no assurance as to whether or when the Offering may be completed, or as to the actual size or terms of the Offering. Lithium Americas also expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the Common Shares (the “Over-Allotment Option”).

Key Points: 
  • VANCOUVER, British Columbia, April 17, 2024 (GLOBE NEWSWIRE) -- Lithium Americas Corp. (TSX: LAC) (NYSE: LAC) (“Lithium Americas” or the “Company”) announced that it intends to offer and sell, subject to market conditions, 55,000,000 of its common shares (the “Common Shares”) in an underwritten public offering (the “Offering”).
  • All of the Common Shares to be sold in the Offering will be offered by Lithium Americas.
  • Lithium Americas also expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the Common Shares (the “Over-Allotment Option”).
  • The Prospectus Supplements, the Base Shelf Prospectuses and the Registration Statement contain important information about the Company and the proposed Offering.

Intra-Cellular Therapies Announces Proposed Public Offering of Common Stock

Retrieved on: 
星期二, 四月 16, 2024
Sale, Prospectus, J.P. Morgan & Co., RBC Capital Markets, Broadridge Financial Solutions, Morgan Stanley, Vesey Street, Security (finance), SVB Securities, CNS, Form, Therapy, Varick Street, Equity capital markets, 2nd Floor, State Street, Central nervous system, BofA Securities, Attention, Telephone, File

NEW YORK, April 16, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI) (“Intra-Cellular Therapies”), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that it has commenced an underwritten public offering of $500 million of shares of its common stock.

Key Points: 
  • NEW YORK, April 16, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI) (“Intra-Cellular Therapies”), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that it has commenced an underwritten public offering of $500 million of shares of its common stock.
  • In connection with the offering, Intra-Cellular Therapies intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering.
  • All of the shares in the offering will be sold by Intra-Cellular Therapies.
  • J.P. Morgan, Leerink Partners, BofA Securities, Morgan Stanley and RBC Capital Markets are acting as joint book-running managers for the offering.